Open-label Study of Liothyronine in MS

Treatment tested

• Liothyronine

  Thyroid hormone receptor agonist

Inclusion Criteria: * Must meet 2010 McDonald criteria for clinically definite MS * Must be euthyroid * Expanded Disability Status Scale (EDSS) 3.0-7.5 * Patients may be on MS immunomodulating therapies or immunosuppressant therapies during the study Exclusion Criteria: * Known thyroid disease (past or current) * Currently on thyroid replacement therapy * Steroid use within a month of screening * History of coronary artery disease, atrial fibrillation, or other clinically significant cardiac disease * History of adrenal insufficiency * Ongoing renal and/or liver disease * Ongoing severe depression and/or anxiety * Use of carbamazepine, phenytoin, phenobarbital, warfarin, antacids, cholestyramine, colestipol, sucralfate, and rifampin * Known contraindication to using beta-blocker medications * History of alcohol or substance abuse in the past 6 months * Pregnant or nursing * If the investigator feels that participation in this study is not in the best interest of the subject

This study will evaluate the safety and tolerability of synthetic T3, liothyronine. It will establish if there are changes in MS symptoms and if there is a positive effect on markers of neuronal health.